Baxter International cut its annual profit forecast on Friday, citing hurricane-related disruptions at its North Carolina intravenous solutions facility, causing its shares to fall 1.3% in premarket ...

Tocilizumab treatments in patients with noninfectious uveitis demonstrated high rates of success at 1 year follow ups.

A recent shortage of intravenous solutions underscores the need to address the fragile supply chain for infusion therapy ...

The company, which is a key producer for American healthcare providers, was hit by the hurricane when it tore through western ...

Baxter International warned on Friday that hurricane-related disruptions at its North Carolina IV solutions facility could affect its financials through early 2025. Shares of the medical products ...

Now Baxter said it expects to restart a second IV solutions manufacturing line in the coming week ... The plant, which ...

This includes a monthly intravenous (IV) version of Leqembi which will be reviewed by the US Food and Drug Administration ...

Baxter expects to restart a second IV solutions manufacturing line within the next week, the company announced today. Along ...

Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...

Baxter International cut its full-year profit forecast as it continues to wrestle with the shutdown of a North Carolina ...

Read about Baxter's progress in restoring its North Cove facility after Hurricane Helene-related flooding, causing widespread shortages and a $200 million loss.